Clinical Study

A Due

Posted Date: Sep 15, 2020

  • Investigator: Jean Elwing
  • Specialties:
  • Type of Study: Drug

This is a study to assess the safety and efficacy of macitentan and tadalafil combination therapy compared to the respective monotherapies in subjects with pulmonary artery hypertension (PAH).


Adult Men And Women With Who Group 1 Pah In Who Fc Ii Or Iii May Be Eligible For This Research Study. Subjects Must Be Treatment Naïve Or On A Stable Dose Of Era Or Pde-5I Monotherapy. Additional Eligibility Criteria Are Required To Participate. Please Contact A Member Of The Study Team For More Information.


Pulmonary Hypertension, Era, Pde-5 Inhibitor

For More Information:

Jessica Anderson

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.